Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

bupropion

ZYBAN

bupropion (ZYBAN) is a dopamine transporter inhibitor. Associated with Lacuna Pharma Pty Ltd.

TGA: approved NMPA: clinical trials
Patents linked 15
Pipeline programs 35
News articles 1
Drug details — bupropion
Class
—
Route
—
Patents
15
Programs
35
Data quality
0.81
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

bupropion (ZYBAN) is a dopamine transporter inhibitor. Associated with Lacuna Pharma Pty Ltd.

Key facts

INN bupropion
Brand ZYBAN
Mechanism Dopamine transporter inhibitor
Originator Lacuna Pharma Pty Ltd

Mechanism of action

Dopamine transporter inhibitor

Approval history

Authority Status Date
TGA approved —
NMPA clinical trials —

Recent coverage

View all news
FDA Safety Labeling Changes: Impact on Antidepressant Market & Prescribing Trends 2026
High impact AnalysispsychiatryApr 21, 2026

FDA Safety Labeling Changes: Impact on Antidepressant Market & Prescribing Trends 2026

FDA · psychiatry · 5 min

This article examines the FDA's safety labeling changes for antidepressants and their potential effects on market dynamics and prescribing practices by 2026.

Dr. Sarah Mitchell

Pipeline programs

Browse pipeline Sponsor programs
  1. AXS-05 (dextromethorphan and bupropion) oral tablets Phase 3 · Axsome Therapeutics · Major Depressive Disorder
  2. AXS-05 (dextromethorphan-bupropion) Phase 3 · Axsome Therapeutics · Agitation in Patients With Dementia of the Alzheimer's Type
  3. Bupropion Phase 3 · BRIGHT MINDS BIOSCIENCES · Smoking Cessation
  4. Bupropion Phase 3 · BRIGHT MINDS BIOSCIENCES · Tobacco Use Disorder
  5. INTENSIFY BD Phase 3 · Disc Medicine · Bipolar depression
  6. INTENSIFY MDD Phase 3 · Disc Medicine · Major depressive disorder
  7. Nicotine polacrilex, Bupropion Phase 3 · BRIGHT MINDS BIOSCIENCES · Tobacco Use Disorder
  8. AXS-05 (dextromethorphan-bupropion) Phase 2 · Axsome Therapeutics · Treatment Resistant Depression

Related patents

Browse patents Lacuna Pharma Pty Ltd patent hub

  1. US 12357697

    Pharmaceutical compositions comprising bupropion and cysteine

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12156914

    Pharmaceutical compositions comprising bupropion and cysteine

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12102606

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11786488

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11660274

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11433035

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11344514

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11344513

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11331285

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11291639

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11179351

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11179352

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11129826

    Bupropion as a modulator of drug activity

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11123344

    Bupropion as a modulator of drug activity

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10695304

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is bupropion?

bupropion (ZYBAN) is a dopamine transporter inhibitor. Associated with Lacuna Pharma Pty Ltd.

What is the brand name for bupropion?

ZYBAN is a marketed brand name for bupropion. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.